Table 4.
Pathological results in patients with surgery.
| Variable | NACT (n = 28) | NACRT (n = 29) | p | ||
|---|---|---|---|---|---|
| N | % | N | % | ||
| R0 resection | 27 | 73.0%a | 28 | 73.7%a | 0.999 |
| D2 lymphadenectomy | 26 | 92.9% | 25 | 86.2% | 0.611 |
| Laparoscopic surgery | 13 | 46.4% | 17 | 58.6% | 0.431 |
| Tumor diameterb, median (range) | 4.5 (2-16) | 4 (1.5-14) | 0.695 | ||
| LNs resected, median (range) | 37 (17-66) | 25 (11-45) | <0.001 | ||
| Positive LNs, median (range) | 4.5 (1-22) | 2 (1-23) | 0.666 | ||
| LN ratio, median (range) | 0.01 (0-0.35) | 0 (0-0.61) | 0.832 | ||
| Lauren type Intestinal Diffuse Mixed Undetermined |
11 11 6 0 |
39.3 39.3 21.4 0 |
10 12 3 4 |
34.5 41.4 10.3 13.8 |
0.630 |
| Signet ring cells Present Absent |
8 20 |
28.6 71.4 |
7 22 |
24.1 75.9 |
0.704 |
| Lymphatic/vascular invasion Present Absent |
6 22 |
21.4 78.6 |
4 25 |
13.8 86.2 |
0.682 |
| Perineural invasion Present Absent |
13 15 |
46.4 53.6 |
10 19 |
34.5 65.5 |
0.358 |
| Pathological complete response (TRG1) | 3 | 10.7 | 4 | 13.8 | 0.999 |
| Tumor response TRG1 TRG2 TRG3 TRG4 TRG5 |
3 2 14 9 0 |
10.7 7.2 50 32.1 0 |
4 7 17 1 0 |
13.8 24.1 58.6 3.5 0 |
0.019 |
| ypT stage (AJCC 7th edition) T0 T1 T2 T3 T4 |
2 2 8 5 11 |
7.1 7.1 28.6 17.9 39.3 |
4 4 7 8 6 |
13.8 13.8 24.1 27.6 20.7 |
0.490 |
| ypN stage (AJCC 7th edition) N0 N1 N2 N3 |
14 6 6 2 |
50 21.4 21.4 7.2 |
20 6 0 3 |
69.0 20.7 0 10.3 |
0.059 |
| ypTNM stage (AJCC 7th edition) 0 I II III |
3 7 8 10 |
10.7 25.0 28.6 35.7 |
4 9 10 6 |
13.8 31.0 34.5 20.7 |
0.688 |
a
Among intention-to-treat population.
b
Maximum tumor diameter derived from surgical specimen.
LNs, lymph nodes; ypN, pathological N staging after neoadjuvant therapy; ypT, pathological T staging after neoadjuvant therapy; ypTNM, pathological staging after neoadjuvant therapy.